News search

E.g., 02/11/2026
E.g., 02/11/2026
The R33Q mutation in calsequestrin 2 (CASQ2) disrupts calcium control in heart cells and activates protein-degradation mechanisms.
Research
23 Sep 2026

Researchers at the CNIC, in collaboration with the University of Pavia and IRCCS Istituti Clinici Scientifici Maugeri, have found that activation of the enzyme calpain contributes to the development of a severe inherited arrhythmia.

Resonancia magnética de dos pacientes con miocardiopatía dilatada. A la izquierda, paciente con fibrosis sin canales de conducción y a la derecha, paciente con múltiples canales.
Research
8 Sep 2026

The findings could help more precisely identify candidates for a preventive implantable defibrillator

Ana Simón Chica y David Filgueiras Rama
Research
10 Feb 2026

The study, published in Circulation Research, identifies cardiac fibroblasts and resident macrophages as essential contributors to the characteristic electrical activity that maintains this arrhythmia

José Antonio Enríquez, Almudena Ramiro  y Silvia Priori.
About the CNIC
17 Jun 2025

The projects—led by Drs Almudena Ramiro, José Antonio Enríquez, and Silvia Priori—will receive a total of €5.25 million for CNIC research over the next 5 years

María Linarejos Vera, Gema Mondéjar, Amaia Talavera, Patricia Sánchez, Álvaro Macías, Juan Manuel Ruiz, Francisco M. Cruz, Fernando Martínez de Benito, Juan Antonio Bernal y José Jalife
Research
11 Apr 2024

CNIC researchers, led by Dr. José Jalife, have made a key discovery about cardiac arrhythmias in Andersen-Tawil syndrome (ATS)

Imágenes de mapeado óptico de dos corazones distintos de ratones que desarrollaron fibrilación ventricular.
Research
3 Nov 2022

CNIC scientists have identified a molecular mechanism that accounts for the arrhythmias, skeletal muscle weakness, and periodic paralysis in patients with this rare disease

Dr. Pablo García-Pavía y Dr. Jesús Gonzalez Mirelis, codirectores del trabajo.
Research
22 Jul 2022

Genetic screening combined with the detection of fibrosis identifies patients at risk of malignant arrhythmias or developing heart failure with severe complications